{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Paton B"],"pubmed_abstract":["<h4>Background</h4>The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease. Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.<h4>Methods</h4>Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19. Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression. N-glycans were released with PNGase F and labelled "],"journal":["Frontiers in immunology"],"pagination":["1204661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10278543"],"repository":["biostudies-literature"],"pubmed_title":["Fucosylated N-glycans as early biomarkers of COVID-19 severity."],"pmcid":["PMC10278543"],"pubmed_authors":["Peraire J","Martinez-Picado J","Suarez M","Rull A","Del Pino A","Gomez-Bertomeu F","Chafino S","Canela N","Paton B","Herrero P"],"additional_accession":[]},"is_claimable":false,"name":"Fucosylated N-glycans as early biomarkers of COVID-19 severity.","description":"<h4>Background</h4>The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease. Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.<h4>Methods</h4>Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19. Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression. N-glycans were released with PNGase F and labelled ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-19T02:16:42.21Z","creation":"2025-04-07T12:47:11.06Z"},"accession":"S-EPMC10278543","cross_references":{"pubmed":["37342334"],"doi":["10.3389/fimmu.2023.1204661"]}}